Skyrizi (risankizumab) - AbbVie, Boehringer Ingelheim
Skyrizi: Data from P3 trial (NCT03478787) for psoriasis in 2020 (AbbVie) - Feb 8, 2020 - Pipeline Update 
P3 data
https://investors.abbvie.com/static-files/0f2e0201-ef33-432c-904e-8cf78d2d0929
 
Feb 8, 2020
 
 
0a63bbb3-4614-4fbb-b8d4-142544547b48.jpg